Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPACT SHPT: Paricalcitol-centered Therapy vs Cinacalcet + Low-dose Vitamin D in Hemodialysis SHPT
2009-011378-14Phase 4Completed
- Sponsor
- Abbott Laboratories
- Start
- Aug 2009
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of paricalcitol and cinacalcet in secondary hyperparathyroidism (SHPT) (2 arms), sponsored by Abbott Laboratories. Primary endpoint: Proportion of subjects achieving mean iPTH 150–300 pg/mL during Weeks 21–28. Started Aug 2009; status: completed.
02
Drugs
paricalcitolcinacalcet
03
Conditions
secondary hyperparathyroidism (SHPT)
Beyond the preview
Go deeper on 2009-011378-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011378-14.